Skip to main content
Senior woman header
Senior woman header
Photo header of senior man
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE®

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More
Senior woman header
Senior woman header
Senior man header
Photo header of senior man

DIAGNOSTIC INSIGHTS FOR LIFE

CND’s Syn-One Test® offers physicians and patients an accurate, convenient, evidence-based tool to help diagnose a synucleinopathy. And our mission has just begun.

Learn More

Introducing the Syn-One Test® from CND Life Sciences

The first commercially available skin-based test to help clinicians diagnose Parkinson’s disease and related disorders.

seal icon

CLIA-Certified and CAP-Accredited Pathology Lab

test tube icon

Dedication to Science, Research, Quality, and Reliability

DNA icon

Patient-Focused Mission

microscope icon

High Accuracy: >95% Sensitivity and Specificity

Clarity and Confidence of Syn-One

Having objective, visual proof of a disease process can be invaluable for physicians and patients. That’s why CND Life Sciences developed the Syn-One Test as a way to actually see the presence of abnormal alpha-synuclein in the skin–an important marker for Parkinson’s disease and other disorders known as synucleinopathies.  

Learn More

Our Commitment to Patients

We did not invent the saying “knowledge is power,” but we subscribe to this philosophy as part of our mission. Patients and caregivers rely on physicians to make vital clinical judgments every day, and we are committed to providing reliable diagnostic technologies and useful insights that help optimize care.

Learn more about what drives us.

Learn More

CND Insights

Read our perspectives on the industry, the field of neurodiagnostics, patient care, and other topics.

Insights
March 4, 2025

Patient Matters Video Series: Knowledge is Power

In the latest installment of our Patient Matters video series, Daryn Kagan talks with Bill…
Insights
January 28, 2025

A Victory in The Battle for Parkinson’s Disease Prevention

In December 2024, the U.S. Environmental Protection Agency (EPA) announced a plan to limit and…
Insights
December 13, 2024

The Skin May Offer Clues About Parkinson’s Disease and Its Progression Over Time

CND Life Sciences is conducting a clinical research study to learn more about the progression…
VIEW ALL INSIGHTS

News

Check out press releases, news alerts and coverage of CND happenings.

CND In the News
March 27, 2025

CND Life Sciences to Present Updates from Three Clinical Trials Involving Their Skin Biopsy Diagnostic Tool for Dementia and Other Related Disorders at the American Academy of Neurology 2025 Annual Meeting

CND Life Sciences (CND), a medical technology company pioneering the development of cutaneous neurodiagnostic tests and…
On Our Radar
March 19, 2025

ATH434 Slowed Disease Progression in Multiple System Atrophy Study

Alterity Therapeutics released topline results from its Phase 2 trial of ATH434-201 in patients with…
On Our Radar
March 10, 2025

Hearing Impairment Associated With Increased Risk of Parkinson’s Disease

Although Parkinson’s disease primarily presents with motor symptoms, other non-motor symptoms, such as depression, anxiety,…
VIEW ALL NEWS
CND CASE STUDIES

For Clinicians: Request a Skin Biopsy Test Kit

Our suite of neurodiagnostic tests provides clinicians with objective pathological insights on diseases that are often difficult to diagnose. Using our Skin Biopsy Test Kit, collect three small skin biopsies from your patient, send them to our CLIA-certified and CAP-accredited lab, and CND will provide important pathological insights to support a diagnosis.

Order a Kit